Fabric Proven to Reduce MRSA Acquisition and Retention
Orlando, FL – Vestagen Technical Textiles, Inc., today announced that existing investor Advent Life Sciences was joined by new investors Sofinnova HealthQuest Capital and the Clearwell Group bringing total investments to $15.5 million.
The additional funds will support expanded commercialization of Vestex®, the first in a new class of active barrier protective fabrics for everyday use that are clinically proven to prevent or reduce the acquisition and retention of microbes and other contaminants. Vestex is engineered to have robust liquid repellency and embedded antimicrobial properties, along with enhanced breathability, good durability and affordability. The company’s initial focus is on medical scrubs and other protective apparel for healthcare workers, who are at daily risk of exposure to dangerous contaminants and who can unknowingly spread these contaminants to other workers, patients and family members.
“This financing extension reflects our investors’ confidence in the transformative potential of our Vestex fabric,” said Uncas “Ben” B. Favret III, president and CEO of Vestagen. “Since our initial close we have recruited world-class executives who are advancing our product launch and partnering initiatives, as well as the FDA regulatory process for review of Vestex as a protective medical device. The response to date from potential customers and partners has been excellent, and we look forward to reporting on our progress in the coming months.” Continue>
Posted in: Safety First | September 19, 2013
Posted in: Safety First | June 30, 2014
Posted in: Safety First | July 29, 2015